Allogene Therapeutics, Inc. (ALLO): auditor change — Allogene restates 2020-2022 financials; material weakness in ICFR identified

Allogene Therapeutics, Inc.

Audit Committee determined 2020-2022 annual and 2021-2023 quarterly reports should no longer be relied upon.
Error: equity method investment in Allogene Overland (49% stake) initially recorded at zero; should be fair value.
Restatement will record non-cash adjustments for seed preferred shares fair value and share of JV losses.
Management and EY concluded internal control over financial reporting was ineffective; material weakness identified.
Company targets filing restated 2022 10-K by March 14, 2024; no impact on cash or cash equivalents.

item 4.02

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Allogene Therapeutics, Inc. reported that prior financial statements should not be relied upon.

Action: non reliance
Auditor: Ernst & Young LLP

Exact text from the filing

on February 14, 2024, the Company’s Audit Committee of the Board of Directors of the Company (the “Audit Committee”) determined, based on management’s recommendation and after consultation with Ernst & Young LLP, the Company’s independent registered public accounting firm, that the Seed Preferred Shares should have been initially measured at fair value, and the accounting for the Seed Preferred Shares should be restated. As a result, the Audit Committee also determined that the Company’s financial statements for the years ended December 31, 2020, 2021 and 2022, and in each of the Company’s quarterly reports on Form 10-Q filed with the SEC in 2021, 2022 and 2023 (collectively, the “Restatement Periods”), should no longer be relied upon

View on SEC.gov

8 auditor changes filed in the last 30 days. Browse all auditor changes →

Allogene Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-038107

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.